Six-Gene Predictive Biomarker Identified for Use in Breast Cancer
REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab (anti-Fzd7, OMP-18R5) at the San Antonio Breast Cancer Symposium (SABCS). The presentation at SABCS detailed the identification and validation of a novel six-gene signature assay being evaluated as a predictive biomarker of response to vantictumab plus paclitaxel in the treatment of breast cancer. Vantictumab is being studied in three Phase 1b combination clinical trials, including one with paclitaxel in patients with Her2-negative breast cancer.
"The research presented today is one example of OncoMed's efforts to identify biomarkers early and aggressively that can be evaluated alongside our therapeutic candidates in order to optimize treatment regimens and patient outcomes," said John Lewicki, Ph.D. Executive Vice President and Chief Scientific Officer of OncoMed. "In preclinical testing, the six-gene biomarker assay has been strongly predictive of anti-tumor responses to treatment with vantictumab in Her2-negative breast cancers. If these results are corroborated in our ongoing clinical study of vantictumab in breast cancer, it will provide an excellent opportunity to develop a companion diagnostic and tailor vantictumab use to patients with the highest likelihood of benefit."
The six-gene Wnt pathway-related biomarker was identified by using gene expression data from breast cancer xenografts in OncoMed's patient-derived tumor bank with established in vivo response to vantictumab plus standard-of-care. The six-gene signature was tested in 18 xenograft models and effectively predicted anti-tumor responses to treatment. The biomarker was developed as a robust qPCR assay and validated with repeatability studies conducted across different days and in different labs. Prevalence of the six-gene signature is estimated to be approximately 43 percent in Her2-negative patients. In collaboration with Almac Diagnostics, the assay has been successfully developed and is being deployed in OncoMed's ongoing Phase 1b study of vantictumab in Her2-negative breast cancer.
These data were presented in a poster titled Development of a 6-gene qPCR RUO-validated assay as a predictive biomarker for response of vantictumab (OMP-18R5; anti-frizzled) in HER2- breast cancer patients (# P3-07-57) during the "Prognostic and Predictive Factors: Response Predictions — Biomarkers and Other Factors" poster session.
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=946711
The Centers for Disease Control and Prevention report 86 million American adults have prediabetes, and of those, as many as a third will become diabetics within five years.
Omada Health has revealed promising results from a study that looked at how well its digital health tools could help spur weight loss among Medicare members, a milestone for the company a couple of months after it roped in new funding to develop its health management program.
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
Preclinical Comparison Study Shows Improved Anti-Tumor and Immune Responses for Anti-DLL4/VEGF Bispecific Plus Anti-PD1 vs. Either Alone
Silk Road Medical Announces up to $57 Million in New Funding for Novel Approach to Preventing Strokes
Via: PR Newswire
Financing to Support Commercialization of First-in-Class Products for TransCarotid Artery Revascularization (TCAR) Procedure
Via: MedCity News
A few months after Outset Medical’s huge fundraise to support the clinical roll outof its Tablo dialysis system — one of the largest medtech funding rounds this year — CEO Leslie Trigg spoke at Heath 2.0 about how the company wants to transform how we think of dialysis. Aside from adding musical functions and animation and collaborating with the likes of DaVita, it wants to give patients access to their dialysis data.
Omada Health, which just nabbed $48 million in new funding, expects to have "hundreds of thousands" of health plan enrollees using its digital health services by next year, CEO Sean Duffy says.
OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today presented preclinical data for the company's proprietary, wholly owned GITRL-Fc agent during the afternoon poster session of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
Omada Health, which provides a digital program based on the landmark NIH diabetes prevention study, raised $48 million, bringing total funding to $77.5 million. The series C round was led by Norwest Venture Partners, and includes returning investors Andreessen Horowitz and US Venture Partners, among others. Accelerator-turned venture fund Rock Health which nurtured Omada in its first class of digital health startups, also reinvested.
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic Cancer
Enrollment of 177 Patients Completed Over Eight Months Ahead of Schedule